Expertise in
4
conditions

Dr. Amit R. Saxena

Rheumatology
Nyu Langone Health-Center For Arthritis & Autoimmunity
333 E 38th St Fl 4, 
New York, NY 
Offers Telehealth
Referral may be required
Before you request
Expertise in
4
conditions
Nyu Langone Health-Center For Arthritis & Autoimmunity
333 E 38th St Fl 4, 
New York, NY 

Overview

Amit Saxena is a Rheumatologist practicing medicine in New York, New York.

Dr. Saxena is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Mixed Connective Tissue Disease.

He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 9 clinical trials.

Specialties

Rheumatology

Licenses

Internal Medicine in NY

Hospital Affiliations

Bellevue Hospital Center
Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Nyu Langone Health-Center For Arthritis & Autoimmunity
333 E 38th St Fl 4, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)
Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)
Enrollment Status: Terminated
Publish Date: June 10, 2026
Intervention Type: Drug, Biological
Study Drugs: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, IS (MMF or MPA), IS (MTX), IS (B cell Depletion Therapy)
Study Phase: Phase 2
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: March 20, 2026
Intervention Type: Other, Biological
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drugs: Lisinopril, Benazepril
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: August 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial
Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Drug
Study Phase: Phase 2
Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus
Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus
Enrollment Status: Withdrawn
Publish Date: September 13, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

98 Total Publications

Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation.
Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation.
Journal: Research square
Published: September 03, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (1.9 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist practicing medicine in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

Hospital For Special Surgery-Main Hospital

535 E 70th St Fl 6, 
New York, NY 
 (2.0 miles away)
212-606-1163
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Goodman is a Rheumatologist practicing medicine in New York, New York. Dr. Goodman is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, Knee Replacement, and Hip Replacement.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required
Before you request

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (0.9 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alice Gottlieb is a Rheumatologist practicing medicine in New York, New York. Dr. Gottlieb is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, and Arthritis. Dr. Gottlieb is currently accepting new patients.

Frequently Asked Questions about Dr. Amit R. Saxena

How do I make an appointment with Dr. Amit R. Saxena?

You can book an appointment with Dr. Amit R. Saxena by calling their office at 646-501-7400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amit R. Saxena a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amit R. Saxena is classified as an Distinguished expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amit R. Saxena specialize in?

While Dr. Amit R. Saxena is a Rheumatology, they have specific expertise in Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Undifferentiated Connective Tissue Disease (UCTD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Amit R. Saxena participate in research or clinical trials?

Yes. Dr. Amit R. Saxena has published 98 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Dr. Amit R. Saxena's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amit R. Saxena accept my insurance?

Dr. Amit R. Saxena accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 646-501-7400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saxena's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile